Boston Partners
NEOS

Boston Partners’s Neos Therapeutics, Inc NEOS Stock Holding History

Boston Partners’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-229,485
Closed -$347K – 772
2019
Q4 		$347K Buy
+229,485
New +$344K ﹤0.01% 629

Other funds holding NEOS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Boston Partners's NEOS Position: Q1 2020 in Review

Boston Partners sold out of Neos Therapeutics, Inc (NEOS) in Q1 2020, closing a stake of 229,485 shares — an estimated $347K sold.

Boston Partners first reported a position in NEOS in Q4 2019 and held it in 1 quarter. The position peaked at $347K in Q4 2019. 49 funds tracked by Wall St. Rank hold NEOS as of Q1 2020.

  • Boston Partners reported no remaining Neos Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • Boston Partners sold 229,485 Neos Therapeutics, Inc shares in Q1 2020, an estimated $347K.
  • Boston Partners first reported a position in Neos Therapeutics, Inc in Q4 2019 and held it in 1 quarter.
  • Boston Partners's Neos Therapeutics, Inc position peaked at $347K in Q4 2019.
  • 49 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q1 2020.

Based on Boston Partners's 13F filing for Q1 2020, filed 13 May 2020.